Buying TB-500 in the USA: It Is Not Thymosin Beta-4

TB-500 and thymosin β4 get used as though they were two names for one substance. They are not, and the conflation makes a sizeable body of literature harder to read than it needs to be.

One trade name, several sequences

This is the most consequential practical point on the page, so it goes first. “TB-500” is a commercial designation rather than a defined chemical name, and material circulating under it varies in length and in whether the N-terminus is acetylated. Two vials from two suppliers can both be labeled TB-500 and contain peptides of different mass.

It follows that a certificate reporting only a purity percentage is insufficient here. Mass confirmation against a stated sequence is what establishes which fragment is actually in hand, and with no stated sequence on the certificate the mass has nothing to be checked against. When comparing suppliers, compare sequences rather than names. Nomenclature conventions across analogs and fragments are covered in peptide nomenclature.

The protein, and what a fragment of it carries

Thymosin β4 is a 43-residue protein and one of the most abundant intracellular proteins in many cell types. Its best-characterized function is the sequestration of monomeric G-actin, which places it at the center of actin cytoskeletal dynamics; because actin polymerization underlies cell migration, the protein turns up throughout the cell-motility literature. See PubMed.

TB-500 is a synthetic peptide corresponding to the actin-binding region of that protein: a short sequence containing the motif responsible for G-actin binding, not the full protein. The rationale for working with the fragment is straightforward, in that it is far cheaper to synthesize than a 43-residue protein while retaining the actin-binding determinant.

The determinant in question is a hexapeptide motif, LKKTET, located within the central helical region of thymosin β4. That motif makes the contact with G-actin, and it is why a fragment containing it retains actin-sequestering activity at all. Peptides sold as TB-500 correspond to the region around the motif rather than to any single universally agreed sequence, which is exactly why the identity question above matters.

Worth noting too: thymosin β4 is intrinsically disordered in solution. It has no stable fold on its own and takes up helical structure only on binding actin. A short fragment is therefore not “the folded part” of the protein, because there is no folded part. What the fragment carries is a linear recognition motif, and the residues around it modulate how well that motif is presented.

What does not transfer from protein to fragment

Thymosin β4 has reported activities not attributed to the actin-binding motif alone, and a fragment cannot be assumed to reproduce them. Where a paper reports an effect of the protein, that finding does not automatically carry over to TB-500, and the reverse holds equally.

• Actin sequestration at scale. The intact protein is abundant enough intracellularly to act as a genuine buffer for the monomeric actin pool. A fragment supplied exogenously at micromolar concentrations is not doing that job.
• Interactions outside the actin motif. Reported activities attributed to regions of the protein other than LKKTET do not transfer to a fragment lacking those regions.
• Processing products. Thymosin β4 is itself cleaved in vivo into shorter products, notably the N-terminal tetrapeptide Ac-SDKP, which has a literature of its own. A synthetic fragment corresponding to the actin-binding region is not that molecule either.
• Charge and solubility behavior. A 43-residue polyanionic protein and a short cationic-leaning fragment do not behave alike in a buffer, on a column, or against plasticware.

Reading the literature without conflating the two

Nearly every practical problem in this area starts with a search that returns both molecules under one heading. Four checks resolve it.

• Identify the molecule from the methods, not the title. Papers frequently say “Tβ4” in the abstract and then specify a synthetic fragment in the methods, or the other way around.
• Check the stated sequence and length. A 43-residue protein and a fragment of a dozen or so residues are different entities, and the paper should say which was used.
• Convert concentrations properly. Molar and mass concentrations diverge by roughly a factor of three or four between the protein and a short fragment, so a study reporting micrograms per milliliter is not directly comparable with one reporting micromolar until the arithmetic is done.
• Note the source. Recombinant protein, chemically synthesized protein and synthetic fragment carry different impurity profiles, and endotoxin in particular is a live question for recombinant material but not for solid-phase synthesis.

Assays that answer the question

Where the question is whether a given fragment behaves as expected, these are the readouts that address it.

• Pyrene-actin polymerization. The standard biochemical assay. Fluorescently labeled G-actin gains signal on polymerization, and a sequestering agent slows the reaction or lowers the plateau. It gives a direct, cell-free measure of actin binding.
• Sedimentation assays. Ultracentrifugation separates F-actin from G-actin, and the ratio reports sequestration without any fluorophore.
• Isothermal titration calorimetry or fluorescence anisotropy, for binding affinity to G-actin measured directly.
• Scratch and transwell migration assays in cell culture, with migration as the downstream readout. Useful, but several inferential steps removed from the binding event and sensitive to proliferation as a confounder, so a proliferation control belongs in the design.
• Circular dichroism, to confirm the disorder-to-helix transition on actin binding where the mechanism itself is in question.

Whichever is chosen, an intact thymosin β4 comparator arm is what makes a fragment result interpretable. Without one, the study measures the fragment against nothing.

Analytical characterization

• Mass confirmation against a stated sequence. The priority for this compound, for the reasons set out above: ESI-MS or MALDI-TOF against the calculated mass, with acetylation accounted for where present. Since several actin-binding-region fragments of differing length circulate under the same trade name and are not the same molecule, this is the check that establishes identity. Our note on why certificates disagree covers what else to look for.
• RP-HPLC purity with gradient, column and wavelength stated. Deletion sequences differing by a single residue elute close to the main peak and disappear under a steep gradient.
• Net peptide content. Lyophilized material carries counterions and residual water, so gross vial mass overstates peptide mass, commonly by fifteen to twenty-five percent. See net peptide content explained.
• Counterion identity. Residual trifluoroacetate has activity of its own in cell assays, which is relevant here because migration assays are cell-based. See counterions and salt form.
• Endotoxin is not established by HPLC or MS. Where the readout is immune or inflammatory it requires its own test. See endotoxin and sterility.

Handling and storage

Short, largely hydrophilic peptides of this type reconstitute readily in water or a near-neutral buffer and are unremarkable to handle, subject to three caveats. Aliquot on reconstitution so that no tube is thawed twice, since repeated freeze–thaw cycles promote aggregation and adsorption losses that lower effective concentration invisibly. Use low-binding plasticware at low working concentrations. And treat solution age, not vial age, as the variable governing fitness for use. Conditions are in storage and stability, documentation in keeping a peptide inventory.

On the blends

TB-500 is frequently supplied blended with BPC-157. For experimental purposes a blend is a single formulation carrying two variables, and any result from it is attributable to neither component individually without single-agent arms. The stated split matters as well: a 10mg blend at 5mg plus 5mg and a 20mg blend at 10mg plus 10mg are different concentrations of each component rather than simply more of the same thing. The limits of what the BPC-157 literature actually supports are set out in BPC-157 and the limits of the published literature.

Terms used here

• Thymosin β4 (Tβ4) — 43-residue intracellular protein; the principal G-actin sequestering protein in many cell types.
• TB-500 — commercial designation for synthetic peptides corresponding to the actin-binding region; not a defined sequence.
• LKKTET — the hexapeptide motif responsible for G-actin binding.
• G-actin / F-actin — monomeric and filamentous actin respectively.
• Sequestration — binding monomer so that it is unavailable for polymerization, as distinct from capping or severing filaments.
• Intrinsically disordered — no stable fold in isolation; structure adopted on binding a partner.
• Ac-SDKP — N-terminal tetrapeptide processing product of thymosin β4, with a separate literature.

Products: TB-500 5mg, TB-500 10mg, TB-500 and BPC-157 blend.

ExoLabz supplies compounds for laboratory research use only. Nothing on this page is medical advice or a suggestion of human or veterinary use. The third-party reports we have obtained are published on our certificates of analysis page.

If you’re choosing between TB-500 and BPC-157, the BPC-157 vs TB-500 comparison puts both side by side.